Saturday, September 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 12, 2026

Applied Materials AMAT Q1 2026 Earnings Transcript

View original at nasdaq.com
Applied Materials AMAT Q1 2026 Earnings Transcript Image source: The Motley Fool. Date Thursday, February 12, 2026 at 4:30 p.m…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Services growth is supported by expanding installed base, higher attachment to performance-based agreements, and analytics-driven optimization

    80% confidence
  • Gate-all-around and backside power introduce new materials and integration challenges where company's leadership in materials engineering is a key differentiator

    80% confidence
  • Applied Materials differentiates with a comprehensive toolset across wafer-level packaging, hybrid bonding, and inspection/metrology

    80% confidence
  • Advanced packaging is a strong growth vector driven by heterogeneous integration and AI

    80% confidence
  • Metrology and inspection are growing as process complexity increases, with e-beam and optical platforms gaining traction

    80% confidence
  • Applied Materials delivered solid results in Q1 2026, driven by strong demand across AI, foundry-logic, and memory

    80% confidence
  • Applied Materials is well positioned for gate-all-around and backside power transitions with broad suite of solutions

    80% confidence
  • Company has seen some timing shifts typical for the industry, but no material cancellations; overall demand signals remain constructive

    80% confidence
  • DRAM WFE is leading the recovery, particularly with HBM-driven investments, while NAND is improving at a slower pace

    80% confidence
  • Integrated solutions help customers improve line-edge roughness, CD control, and defectivity, critical as EUV moves deeper into HVM and to higher NA

    80% confidence
  • ICAPS demand remains healthy, supporting power, automotive, and industrial applications, though growth is moderating from peak levels

    80% confidence
  • R&D priorities include gate-all-around, backside power, advanced packaging, EUV adjacencies, new materials for scaling, and expanding metrology/inspection capabilities with AI-driven analytics

    80% confidence
  • OpEx will grow at a measured pace focused on R&D and customer enablement, with discipline on overhead

    80% confidence
  • Visibility for HBM-related tools extends through multiple quarters given customers' capacity plans

    80% confidence
  • Capital allocation priorities remain: invest in business for long-term growth, maintain strong balance sheet, and return excess cash through buybacks and dividends

    80% confidence
  • Pipeline and customer engagements give confidence in demand durability over the coming quarters

    80% confidence
  • Pricing remains rational, reflecting the value of performance and total cost of ownership; competitive dynamics are stable

    80% confidence
  • Company closely monitors regulatory developments, including CFIUS-related matters; outlook reflects current regulatory environment with appropriate assumptions incorporated

    80% confidence
  • Global footprint and broad portfolio allow supporting customers across regions within the regulatory framework

    80% confidence
  • Company expects to continue repurchasing shares at a steady pace while funding strategic investments

    80% confidence
  • Company is investing in automation and remote capabilities to enhance uptime and yield for customers

    80% confidence
  • Gross margin will reflect product and customer mix, as well as continued improvements in productivity and cost, expected to trend favorably as mix normalizes and cost actions take hold

    80% confidence
  • Services margins are stable to improving, supported by higher attachment, software content, and productivity initiatives

    80% confidence
  • Company is focused on operational discipline and supply chain execution to meet customer demand while advancing technology leadership

    80% confidence
  • Regionally, continued momentum in the U.S. and Taiwan, with activity picking up in Korea

    80% confidence
  • Company continues to target a balanced long-term model with operating leverage as revenue scales

    80% confidence
  • Backlog remains elevated with a book-to-bill around unity; working through backlog as supply improves

    80% confidence
  • Services mix continues to shift toward performance-based contracts

    80% confidence
  • Applied Materials returned capital to shareholders through repurchases and dividends, and continues to invest in R&D and capacity to support long-term growth

    80% confidence
  • Foundry-logic remains healthy with strength at leading nodes, while memory is improving, led by DRAM and HBM-related investments

    80% confidence

Data points we hold from this source

Applied Materials, Inc. · book to bill ratio1.0 ratio
Applied Materials, Inc. · backlogelevated qualitative
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com
Applied Materials AMAT Q1 2026 Earnings Transcript — Source | Via News | Via News